Unichem Laboratories Limited has informed the Exchange regarding Board meeting held on May 22, 2025.
UNICHEMLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Unichem Laboratories reported its Q4 and full-year FY25 results, with consolidated revenue from operations growing 18.2% YoY to ₹2,110.97 crores (₹1,785.11 crores in FY24) and standalone revenue up 20.3% to ₹1,735.70 crores. The company swung back to a consolidated profit after tax of ₹137.52 crores from a loss of ₹93.76 crores in FY24, with basic EPS of ₹19.53 versus ₹(13.32). Q4 FY25 consolidated PAT stood at ₹52.97 crores versus a loss of ₹136.74 crores in the year-ago quarter. Statutory auditors N.A. Shah Associates LLP issued an unmodified opinion on both consolidated and standalone results. Comparatives were restated to include the Bayshore Pharmaceuticals (USA) acquisition from Ipca Laboratories. The board also re-appointed cost, secretarial, and internal auditors for FY26.
Strong financial turnaround and robust revenue growth are positive for shareholders. However, the company reported negative consolidated operating cash flow of ₹137.36 crores in FY25 (vs ₹14 crores inflow last year), driven by higher working capital needs, which warrants attention despite the profit recovery.